Retrospective analysis of patients with lupus nephritis: data from a large clinical immunological center in Hungary.
The aim of this study was to review the development, histological type and outcome of 117 patients with lupus nephritis managed and followed by the Division of Clinical Immunology, 3rd Department of Internal Medicine, University of Debrecen, Debrecen, Hungary. The method used was a retrospective study in 117 patients with lupus nephritis followed between 1974 and 2004. The average occurrence of lupus nephritis was 3 (women) and 4.4 (men) years later after the diagnosis of systemic lupus erythematosus, 43 (46.2%) patients had class IV lupus nephritis. The initial therapy was intravenous cyclophosphamide treatment for 6 months in 37 (31.6%) patients. End-stage renal disease had developed in nine (7.6%) patients. The 5-year survival rate was 99.1%. Despite the well-known and proved risk factors like hypertension, high serum creatinine, renal failure at onset or membranous glomerulonephritis, the outcome of the disease in our patient population was more favourable than one would expect according to the data available in the literature. The authors would like to draw attention to the importance of systematic care of patients with systemic lupus erythematosus, which may lead to a better clinical outcome.
Brugos
B
B
Division of Clinical Immunology, 3rd Department of Internal Medicine, University of Debrecen, Debrecen, Hungary.
Kiss
E
E
Szodoray
P
P
Szegedi
G
G
Zeher
M
M
D000328:Adult; D015331:Cohort Studies; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D006814:Hungary; D008180:Lupus Erythematosus, Systemic / Q000145:classification / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008181:Lupus Nephritis / Q000145:classification / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000276:immunology / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D016896:Treatment Outcome